The stock price of AbbVie reached its 52-week high of around $121 just last week before a recent sell-off in ABBV stock, especially after the U.S. FDA stated that all janus kinase inhibitors approved for arthritis treatment should carry a heart-risk warning on the label - sending the stock to lower.
The stock price of AbbVie reached its 52-week high of around $121 just last week before a recent sell-off in ABBV stock, especially after the U.S. FDA stated that all janus kinase inhibitors approved for arthritis treatment should carry a heart-risk warning on the label - sending the stock to lower.
Share this Article
Recommended